Hi Grateful! The only conclusive results we'll get from this trial are mtd and confirmation of p53 activation or not. We'll likely gain some biomarker knowledge which will be used to streamline population choice in future trials. Good biomarker info in a phI can save a company an incredible amount of money, allowing them to target cancers specific to their drugs activity - helping to ensure future trial efficiency and save dramatically on costs moving towards approval. So we'll gain a lot - but as far as conclusive results go - it'll just be mtd and activation proof or lack of.